Hypertension Research
Online ISSN : 1348-4214
Print ISSN : 0916-9636
ISSN-L : 0916-9636
Effects of Intravenously Administered C-type Natriuretic Peptide in Humans: Comparison with Atrial Natriuretic Peptide
Toshio IgakiHiroshi ItohShin-ichi SugaNorio HamaYoshihiro OgawaYasato KomatsuJun YamashitaKentaro DoiTaeHwa ChunKazuwa Nakao
Author information

1998 Volume 21 Issue 1 Pages 7-13


We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43nmol/kg) and α-hANP (0.43 and 0.043nmol/kg) to healthy humans. The experiments were done on different days in thesame five healthy volunteers (31±1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3±1.3, -4.1±1.0mmHg) with a significant increase in heart rate (+7.6±2.6bpm), and exerted significant diuretic and natriuretic activities (+130±80%, +160±100% over the basal level). These effects of CNP (0.43nmol/kg) were comparable to, or less than, those of α-hANP (0.043nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP. (Hypertens Res 1998; 21: 7-13)

Content from these authors
© The Japanese Society of Hypertension
Previous article Next article